Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 134

1.

Quality of Response in Acute Myeloid Leukemia: The Role of Minimal Residual Disease.

Maurillo L, Bassan R, Cascavilla N, Ciceri F.

Cancers (Basel). 2019 Sep 23;11(10). pii: E1417. doi: 10.3390/cancers11101417. Review.

2.

Health-related quality of life of newly diagnosed chronic myeloid leukemia patients treated with first-line dasatinib versus imatinib therapy.

Efficace F, Stagno F, Iurlo A, Breccia M, Cottone F, Bonifacio M, Abruzzese E, Castagnetti F, Caocci G, Crugnola M, Capodanno I, Martino B, Tiribelli M, Patriarca A, Gozzini A, Pregno P, Saussele S, Cascavilla N, Fozza C, Bergamaschi M, Binotto G, Vignetti M, Rosti G.

Leukemia. 2019 Sep 2. doi: 10.1038/s41375-019-0563-0. [Epub ahead of print]

PMID:
31477798
3.

Phase II trial with sequential clofarabine and cyclophosphamide for refractory and relapsed philadelphia-negative adult acute lymphoblastic leukemia. Results of the GIMEMA LAL 1610 protocol.

Bassan R, Fumagalli M, Chiaretti S, Audisio E, Cascavilla N, Paolini S, Delia M, Cerqui E, Micò C, Fabbiano F, Canichella M, Scattolin AM, Perfetti P, Paoloni F, Iodice M, Vitale A, Della Starza I, Fazi P, Vignetti M, Foà R.

Leuk Lymphoma. 2019 Jul 12:1-11. doi: 10.1080/10428194.2019.1639170. [Epub ahead of print]

PMID:
31298059
4.

Real world Italian experience of pomalidomide plus low-dose dexamethasone in the relapsed and refractory myeloma setting: extended follow-up of a retrospective multicenter study by the 'Rete Ematologica Pugliese E Basilicata'.

Mele G, Pastore D, Di Renzo N, Fragasso A, Guarini A, Mazza P, Musto P, Pavone V, Tarantini G, Curci P, Falcone AP, Mele A, Miccolis MR, Palazzo G, Palumbo G, Quinto AM, Reddiconto G, Rizzi R, Cascavilla N, Specchia G, Capalbo SF.

Leuk Lymphoma. 2019 Jul 9:1-4. doi: 10.1080/10428194.2019.1636989. [Epub ahead of print] No abstract available.

PMID:
31286780
5.

Outcome of paraosseous extra-medullary disease in newly diagnosed multiple myeloma patients treated with new drugs.

Montefusco V, Gay F, Spada S, De Paoli L, Di Raimondo F, Ribolla R, Musolino C, Patriarca F, Musto P, Galieni P, Ballanti S, Nozzoli C, Cascavilla N, Ben-Yehuda D, Nagler A, Hajek R, Offidani M, Liberati AM, Sonneveld P, Cavo M, Corradini P, Boccadoro M.

Haematologica. 2019 Jun 20. pii: haematol.2019.219139. doi: 10.3324/haematol.2019.219139. [Epub ahead of print]

6.

Lenalidomide in Pretreated Patients with Diffuse Large B-Cell Lymphoma: An Italian Observational Multicenter Retrospective Study in Daily Clinical Practice.

Broccoli A, Casadei B, Chiappella A, Visco C, Tani M, Cascavilla N, Conconi A, Balzarotti M, Cox MC, Marino D, Goldaniga MC, Marasca R, Tecchio C, Patti C, Musuraca G, Devizzi L, Monaco F, Romano A, Fama A, Zancanella M, Paolini R, Rigacci L, Castellino C, Gaudio F, Argnani L, Zinzani PL.

Oncologist. 2019 Sep;24(9):1246-1252. doi: 10.1634/theoncologist.2018-0603. Epub 2019 Apr 2.

PMID:
30940746
7.

Brentuximab vedotin prior to allogeneic stem cell transplantation increases survival in chemorefractory Hodgkin's lymphoma patients.

Gaudio F, Mazza P, Mele A, Palazzo G, Carella AM, Delia M, Pisapia G, Pastore D, Cascavilla N, Pavone V, Specchia G.

Ann Hematol. 2019 Jun;98(6):1449-1455. doi: 10.1007/s00277-019-03662-6. Epub 2019 Mar 14.

PMID:
30868307
8.

Minimal residual disease and log-reduction of plasma cells are associated with superior response after double autologous stem cell transplant in younger patients with multiple myeloma.

Rossi G, Falcone AP, Minervini MM, De Cillis GP, De Waure C, Sisti LG, Giambra V, Valente D, Chiello V, Scalzulli PR, Carella AM, Cascavilla N.

Cytometry B Clin Cytom. 2019 May;96(3):195-200. doi: 10.1002/cyto.b.21755. Epub 2018 Dec 13.

PMID:
30549231
9.

Is re-challenge still an option as salvage therapy in multiple myeloma? The case of REal-life BOrtezomib re-Use as secoND treatment for relapsed patients exposed frontline to bortezomib-based therapies (the REBOUND Study).

Musto P, Simeon V, Cascavilla N, Falcone A, Petrucci MT, Cesini L, Di Raimondo F, Conticello C, Ria R, Catalano L, Salvatore D, Mastrullo L, Gagliardi A, Villani O, Pietrantuono G, D'Arena G, Mansueto G, Bringhen S, Genuardi M, Di Renzo N, Reddiconto G, Fragasso A, Caravita T, Scapicchio D, Marziano G, Boccadoro M, Mangiacavalli S, Corso A.

Ann Hematol. 2019 Feb;98(2):361-367. doi: 10.1007/s00277-018-3524-1. Epub 2018 Oct 23.

PMID:
30353388
10.

Timing of clopidogrel loading dose on peripheral blood endothelial progenitor cells, SDF-1α and neointimal hyperplasia in carotid stenting.

Di Stolfo G, Mastroianno S, Ruggieri M, Fontana A, Marinucci R, Copetti M, Minervini MM, Savino L, Mastroianno M, Savino M, Pacilli MA, Di Mauro L, Potenza DR, Cascavilla N, Paroni G, Russo A.

Clin Hemorheol Microcirc. 2019;72(1):23-38. doi: 10.3233/CH-180429.

PMID:
30320560
11.

Outcomes of Reduced Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation for Hodgkin Lymphomas: A Retrospective Multicenter Experience by the Rete Ematologica Pugliese (REP).

Gaudio F, Mazza P, Carella AM, Mele A, Palazzo G, Pisapia G, Carluccio P, Pastore D, Cascavilla N, Specchia G, Pavone V.

Clin Lymphoma Myeloma Leuk. 2019 Jan;19(1):35-40. doi: 10.1016/j.clml.2018.08.012. Epub 2018 Sep 12.

PMID:
30293754
12.

Brentuximab vedotin as salvage treatment in Hodgkin lymphoma naïve transplant patients or failing ASCT: the real life experience of Rete Ematologica Pugliese (REP).

Pavone V, Mele A, Carlino D, Specchia G, Gaudio F, Perrone T, Mazza P, Palazzo G, Guarini A, Loseto G, Eleonora P, Cascavilla N, Scalzulli P, Melpignano A, Quintana G, Di Renzo N, Tarantini G, Capalbo S.

Ann Hematol. 2018 Oct;97(10):1817-1824. doi: 10.1007/s00277-018-3379-5. Epub 2018 Jul 27.

PMID:
30054707
13.

A Comparison of the Conditioning Regimens BEAM and FEAM for Autologous Hematopoietic Stem Cell Transplantation in Lymphoma: An Observational Study on 1038 Patients From Fondazione Italiana Linfomi.

Olivieri J, Mosna F, Pelosini M, Fama A, Rattotti S, Giannoccaro M, Carli G, Tisi MC, Ferrero S, Sgherza N, Mazzone AM, Marino D, Calimeri T, Loseto G, Saraceni F, Tomei G, Sica S, Perali G, Codeluppi K, Billio A, Olivieri A, Orciuolo E, Matera R, Stefani PM, Borghero C, Ghione P, Cascavilla N, Lanza F, Chiusolo P, Finotto S, Federici I, Gherlinzoni F, Centurioni R, Fanin R, Zaja F; Fondazione Italiana Linfomi Postgraduate Master Course.

Biol Blood Marrow Transplant. 2018 Sep;24(9):1814-1822. doi: 10.1016/j.bbmt.2018.05.018. Epub 2018 May 29.

14.

Italian real life experience with ibrutinib: results of a large observational study on 77 relapsed/refractory mantle cell lymphoma.

Broccoli A, Casadei B, Morigi A, Sottotetti F, Gotti M, Spina M, Volpetti S, Ferrero S, Spina F, Pisani F, Merli M, Visco C, Paolini R, Zilioli VR, Baldini L, Di Renzo N, Tosi P, Cascavilla N, Molica S, Ilariucci F, Rigolin GM, D'Alò F, Vanazzi A, Santambrogio E, Marasca R, Mastrullo L, Castellino C, Desabbata G, Scortechini I, Trentin L, Morello L, Argnani L, Zinzani PL.

Oncotarget. 2018 May 4;9(34):23443-23450. doi: 10.18632/oncotarget.25215. eCollection 2018 May 4.

15.

Validation of PLASMIC score and follow-up data in a cohort of patients with suspected microangiopathies from Southern Italy.

Tiscia GL, Ostuni A, Cascavilla N, Cappucci F, Scalzulli P, Battista C, Abrescia A, Aucella F, Buquicchio C, Brigante M, D'Andrea G, Di Paolo B, Giordano G, Infante B, Piano S, Ranieri P, Tullo L, Grandone E.

J Thromb Thrombolysis. 2018 Aug;46(2):174-179. doi: 10.1007/s11239-018-1674-6.

PMID:
29737462
16.

Maintenance in myeloma patients achieving complete response after upfront therapy: a pooled analysis.

Cerrato C, Di Raimondo F, De Paoli L, Spada S, Patriarca F, Crippa C, Mina R, Guglielmelli T, Ben-Yehuda D, Oddolo D, Nozzoli C, Angelucci E, Cascavilla N, Rizzi R, Rocco S, Baldini L, Ponticelli E, Marcatti M, Cangialosi C, Caravita T, Benevolo G, Ria R, Nagler A, Musto P, Tacchetti P, Corradini P, Offidani M, Palumbo A, Petrucci MT, Boccadoro M, Gay F.

J Cancer Res Clin Oncol. 2018 Jul;144(7):1357-1366. doi: 10.1007/s00432-018-2641-5. Epub 2018 Apr 19.

PMID:
29675792
17.

Long-Term Results of the FOLL05 Trial Comparing R-CVP Versus R-CHOP Versus R-FM for the Initial Treatment of Patients With Advanced-Stage Symptomatic Follicular Lymphoma.

Luminari S, Ferrari A, Manni M, Dondi A, Chiarenza A, Merli F, Rusconi C, Tarantino V, Tucci A, Vitolo U, Kovalchuk S, Angelucci E, Pulsoni A, Arcaini L, Angrilli F, Gaidano G, Stelitano C, Bertoldero G, Cascavilla N, Salvi F, Ferreri AJM, Vallisa D, Marcheselli L, Federico M.

J Clin Oncol. 2018 Mar 1;36(7):689-696. doi: 10.1200/JCO.2017.74.1652. Epub 2017 Nov 2.

PMID:
29095677
18.

Onset of chronic myeloid leukemia with complex karyotype in a pregnant patient: case report and revision of literature.

Sgherza N, Abruzzese E, Perla G, Minervini MM, Chiello V, Sciannamè N, Cascavilla N.

Ther Clin Risk Manag. 2017 Jun 27;13:751-755. doi: 10.2147/TCRM.S137103. eCollection 2017.

19.

Association between proteomic profile and molecular response in chronic myeloid leukemia patients.

Garrisi VM, Sgherza N, Breccia M, Iacobazzi A, De Tullio G, Nardelli G, Negri A, Divella R, Daniele A, Micelli G, Tufaro A, Cascavilla N, Savino E, Abbate I, Guarini A.

Leuk Lymphoma. 2018 Apr;59(4):1016-1018. doi: 10.1080/10428194.2017.1344841. Epub 2017 Jul 11. No abstract available.

PMID:
28695760
20.

Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study.

Chiappella A, Martelli M, Angelucci E, Brusamolino E, Evangelista A, Carella AM, Stelitano C, Rossi G, Balzarotti M, Merli F, Gaidano G, Pavone V, Rigacci L, Zaja F, D'Arco A, Cascavilla N, Russo E, Castellino A, Gotti M, Congiu AG, Cabras MG, Tucci A, Agostinelli C, Ciccone G, Pileri SA, Vitolo U.

Lancet Oncol. 2017 Aug;18(8):1076-1088. doi: 10.1016/S1470-2045(17)30444-8. Epub 2017 Jun 28.

PMID:
28668386
21.

A comparative analysis of biosimilar vs. originator filgrastim in combination with plerixafor for stem cell mobilization in lymphoma and multiple myeloma: a propensity-score weighted multicenter approach.

Lanza F, Saraceni F, Pezzi A, Martino M, Bosi A, Cascavilla N, Musto P, Zuffa E, Tani M, Cellini C, Laszlo D, Bonifazi F; GITMO (Italian Society for Transplantation).

Am J Hematol. 2017 Sep;92(9):E557-E559. doi: 10.1002/ajh.24817. Epub 2017 Jul 24. No abstract available.

22.

Allogeneic Stem Cell Transplantation for Relapsed/Refractory B Cell Lymphomas: Results of a Multicenter Phase II Prospective Trial including Rituximab in the Reduced-Intensity Conditioning Regimen.

Dodero A, Patriarca F, Milone G, Sarina B, Miceli R, Iori A, Barretta F, Terruzzi E, Mussetti A, Pini M, Bosi A, Dominietto A, Cascavilla N, Onida F, Narni F, Farina L, Rambaldi A, Corradini P.

Biol Blood Marrow Transplant. 2017 Jul;23(7):1102-1109. doi: 10.1016/j.bbmt.2017.03.031. Epub 2017 Apr 5.

23.

Wilms’ Tumor Gene (WT1) Expression and Minimal Residual Disease in Acute Myeloid Leukemia.

Rossi G, Minervini MM, Carella AM, Melillo L, Cascavilla N.

In: van den Heuvel-Eibrink MM, editor. Wilms Tumor [Internet]. Brisbane (AU): Codon Publications; 2016 Mar. Chapter 16.

24.

Health-related quality of life and burden of fatigue in patients with primary immune thrombocytopenia by phase of disease.

Efficace F, Mandelli F, Fazi P, Santoro C, Gaidano G, Cottone F, Borchiellini A, Carpenedo M, Simula MP, Di Giacomo V, Bergamaschi M, Vincelli ID, Rodeghiero F, Ruggeri M, Scaramucci L, Rambaldi A, Cascavilla N, Forghieri F, Petrungaro A, Ditonno P, Caocci G, Cirrincione S, Mazzucconi MG.

Am J Hematol. 2016 Oct;91(10):995-1001. doi: 10.1002/ajh.24463. Epub 2016 Jul 14.

25.

Ruxolitinib - better prognostic impact in low-intermediate 1 risk score: evaluation of the 'rete ematologica pugliese' (REP) in primary and secondary myelofibrosis.

Mazza P, Specchia G, Di Renzo N, Cascavilla N, Tarantini G, Capalbo SF, Urbano T, Albano F, Giovannni R, Falcone AP, Santeramo MT, Spinosa G, Pisconti S.

Leuk Lymphoma. 2017 Jan;58(1):138-144. Epub 2016 Jun 6.

PMID:
27263544
26.

Long-Term Results of the HD2000 Trial Comparing ABVD Versus BEACOPP Versus COPP-EBV-CAD in Untreated Patients With Advanced Hodgkin Lymphoma: A Study by Fondazione Italiana Linfomi.

Merli F, Luminari S, Gobbi PG, Cascavilla N, Mammi C, Ilariucci F, Stelitano C, Musso M, Baldini L, Galimberti S, Angrilli F, Polimeno G, Scalzulli PR, Ferrari A, Marcheselli L, Federico M.

J Clin Oncol. 2016 Apr 10;34(11):1175-81. doi: 10.1200/JCO.2015.62.4817. Epub 2015 Dec 28.

PMID:
26712220
27.

Postpartum haemorrhage in a woman with essential thrombocythemia carrying calreticulin mutation: a case report.

Villani M, Colaizzo D, Tiscia GL, Chinni E, Bodenizza C, Cascavilla N, Grandone E.

Blood Coagul Fibrinolysis. 2016 Sep;27(6):727-8. doi: 10.1097/MBC.0000000000000473.

PMID:
26650457
28.

The use of thrombopoietin-receptor agonists (TPO-RAs) in immune thrombocytopenia (ITP): a "real life" retrospective multicenter experience of the Rete Ematologica Pugliese (REP).

Mazza P, Minoia C, Melpignano A, Polimeno G, Cascavilla N, Di Renzo N, Specchia G.

Ann Hematol. 2016 Jan;95(2):239-44. doi: 10.1007/s00277-015-2556-z. Epub 2015 Nov 24.

PMID:
26596973
29.

Improved outcome of patients with relapsed/refractory Hodgkin lymphoma with a new fotemustine-based high-dose chemotherapy regimen.

Musso M, Messina G, Di Renzo N, Di Carlo P, Vitolo U, Scalone R, Marcacci G, Scalzulli PR, Moscato T, Matera R, Crescimanno A, Santarone S, Orciuolo E, Merenda A, Pavone V, Pastore D, Donnarumma D, Carella AM, Ciochetto C, Cascavilla N, Mele A, Lanza F, Di Nicola M, Bonizzoni E, Pinto A.

Br J Haematol. 2016 Jan;172(1):111-21. doi: 10.1111/bjh.13803. Epub 2015 Oct 12.

30.

Azacitidine in the treatment of older patients affected by acute myeloid leukemia: A report by the Rete Ematologica Pugliese (REP).

Delia M, Carluccio P, Buquicchio C, Vergine C, Greco G, Amurri B, Melpignano A, Melillo L, Cascavilla N, Guarini A, Capalbo S, Tarantini G, Mazza P, Pavone V, Di Renzo N, Specchia G.

Leuk Res. 2015 Aug 20. pii: S0145-2126(15)30358-1. doi: 10.1016/j.leukres.2015.08.005. [Epub ahead of print]

PMID:
26364798
31.

Absolute Monocyte Count and Lymphocyte-Monocyte Ratio Predict Outcome in Nodular Sclerosis Hodgkin Lymphoma: Evaluation Based on Data From 1450 Patients.

Tadmor T, Bari A, Marcheselli L, Sacchi S, Aviv A, Baldini L, Gobbi PG, Pozzi S, Ferri P, Cox MC, Cascavilla N, Iannitto E, Federico M, Polliack A.

Mayo Clin Proc. 2015 Jun;90(6):756-64. doi: 10.1016/j.mayocp.2015.03.025.

32.

Impact of JAK2(V617F) mutation status on treatment response to anagrelide in essential thrombocythemia: an observational, hypothesis-generating study.

Cascavilla N, De Stefano V, Pane F, Pancrazzi A, Iurlo A, Gobbi M, Palandri F, Specchia G, Liberati AM, D'Adda M, Gaidano G, Fjerza R, Achenbach H, Smith J, Wilde P, Vannucchi AM.

Drug Des Devel Ther. 2015 May 18;9:2687-94. doi: 10.2147/DDDT.S79576. eCollection 2015.

33.

Safety and efficacy of single-agent bendamustine after failure of brentuximab vedotin in patients with relapsed or refractory hodgkin's lymphoma: experience with 27 patients.

Zinzani PL, Vitolo U, Viviani S, Corradini P, Motta G, Tani M, Cascavilla N, Hohaus S, Merli F, Argnani L, Broccoli A.

Clin Lymphoma Myeloma Leuk. 2015 Jul;15(7):404-8. doi: 10.1016/j.clml.2015.02.023. Epub 2015 Mar 5.

PMID:
25840816
34.

"Real world" outcome of lenalidomide plus dexamethasone in the setting of recurrent and refractory multiple myeloma: extended follow-up of a retrospective multicenter study by the "rete ematologica pugliese".

Mele G, Melpignano A, Quarta G, Palumbo G, Capalbo S, Falcone A, Cascavilla N, Palazzo G, Mazza P, Iannitto E, Curci P, Rizzi R, Specchia G, Rossini B, Pavone V, Ria R, Vacca A, Buquicchio C, Tarantini G, Minoia C, Guarini A, Ditonno P, Polimeno G, Reddiconto G, Di Renzo N.

Leuk Res. 2015 Mar;39(3):279-83. doi: 10.1016/j.leukres.2014.12.007. Epub 2014 Dec 23.

PMID:
25636354
35.

Optimal time-points for minimal residual disease monitoring change on the basis of the method used in patients with acute myeloid leukemia who underwent allogeneic stem cell transplantation: a comparison between multiparameter flow cytometry and Wilms' tumor 1 expression.

Rossi G, Carella AM, Minervini MM, di Nardo F, Waure Cd, Greco MM, Merla E, Cillis GP, Di Renzo N, Melpignano A, Capalbo S, Palumbo G, Pisapia G, Cascavilla N.

Leuk Res. 2015 Feb;39(2):138-43. doi: 10.1016/j.leukres.2014.11.011. Epub 2014 Nov 29.

PMID:
25498507
36.

Bendamustine and subcutaneous alemtuzumab combination is an effective treatment in relapsed/refractory chronic lymphocytic leukemia patients.

Montillo M, Tedeschi A, Gaidano G, Coscia M, Petrizzi VB, Orlandi E, Cascavilla N, Ghia P, Motta M, Gallamini A, Frustaci AM, Rossi D, De Paoli L, Nichelatti M, Morra E, Massaia M.

Haematologica. 2014 Sep;99(9):e159-61. doi: 10.3324/haematol.2014.106740. Epub 2014 Jun 27. No abstract available.

37.

Results of a multicenter, controlled, randomized clinical trial evaluating the combination of piperacillin/tazobactam and tigecycline in high-risk hematologic patients with cancer with febrile neutropenia.

Bucaneve G, Micozzi A, Picardi M, Ballanti S, Cascavilla N, Salutari P, Specchia G, Fanci R, Luppi M, Cudillo L, Cantaffa R, Milone G, Bocchia M, Martinelli G, Offidani M, Chierichini A, Fabbiano F, Quarta G, Primon V, Martino B, Manna A, Zuffa E, Ferrari A, Gentile G, Foà R, Del Favero A.

J Clin Oncol. 2014 May 10;32(14):1463-71. doi: 10.1200/JCO.2013.51.6963. Epub 2014 Apr 14.

PMID:
24733807
38.

Predictive role of minimal residual disease and log clearance in acute myeloid leukemia: a comparison between multiparameter flow cytometry and Wilm's tumor 1 levels.

Rossi G, Minervini MM, Melillo L, di Nardo F, de Waure C, Scalzulli PR, Perla G, Valente D, Sinisi N, Cascavilla N.

Ann Hematol. 2014 Jul;93(7):1149-57. doi: 10.1007/s00277-014-2029-9. Epub 2014 Feb 20.

PMID:
24554303
39.

Safety and efficacy of (90) yttrium-ibritumomab-tiuxetan for untreated follicular lymphoma patients. An Italian cooperative study.

Ibatici A, Pica GM, Nati S, Vitolo U, Botto B, Ciochetto C, Petrini M, Galimberti S, Ciabatti E, Orciuolo E, Zinzani PL, Cascavilla N, Guolo F, Fraternali Orcioni G, Carella AM.

Br J Haematol. 2014 Mar;164(5):710-6. doi: 10.1111/bjh.12695. Epub 2013 Dec 17.

PMID:
24344981
40.

Bendamustine in combination with ofatumumab in relapsed or refractory chronic lymphocytic leukemia: a GIMEMA Multicenter Phase II Trial.

Cortelezzi A, Sciumè M, Liberati AM, Vincenti D, Cuneo A, Reda G, Laurenti L, Zaja F, Marasca R, Chiarenza A, Gritti G, Orsucci L, Storti S, Angelucci E, Cascavilla N, Gobbi M, Mauro FR, Morabito F, Fabris S, Piciocchi A, Vignetti M, Neri A, Rossi D, Giannarelli D, Guarini A, Foà R.

Leukemia. 2014 Mar;28(3):642-8. doi: 10.1038/leu.2013.334. Epub 2013 Nov 13.

PMID:
24220274
41.

Lenalidomide and low-dose dexamethasone for newly diagnosed primary plasma cell leukemia.

Musto P, Simeon V, Martorelli MC, Petrucci MT, Cascavilla N, Di Raimondo F, Caravita T, Morabito F, Offidani M, Olivieri A, Benevolo G, Mina R, Guariglia R, D'Arena G, Mansueto G, Filardi N, Nobile F, Levi A, Falcone A, Cavalli M, Pietrantuono G, Villani O, Bringhen S, Omedè P, Lerose R, Agnelli L, Todoerti K, Neri A, Boccadoro M, Palumbo A.

Leukemia. 2014 Jan;28(1):222-5. doi: 10.1038/leu.2013.241. Epub 2013 Aug 20. No abstract available.

PMID:
23958922
42.

Factors affecting successful mobilization with plerixafor: an Italian prospective survey in 215 patients with multiple myeloma and lymphoma.

Lanza F, Lemoli RM, Olivieri A, Laszlo D, Martino M, Specchia G, Pavone V, Imola M, Pasini A, Milone G, Scortechini I, Todisco E, Guggiari E, Cascavilla N, Martinelli G, Rambaldi A, Bosi A.

Transfusion. 2014 Feb;54(2):331-9. doi: 10.1111/trf.12265. Epub 2013 Jun 19. Erratum in: Transfusion. 2014 Jun;54(6):1688-91.

PMID:
23781769
43.

Minimal residual disease after allogeneic stem cell transplant: a comparison among multiparametric flow cytometry, Wilms tumor 1 expression and chimerism status (Complete chimerism versus Low Level Mixed Chimerism) in acute leukemia.

Rossi G, Carella AM, Minervini MM, Savino L, Fontana A, Pellegrini F, Greco MM, Merla E, Quarta G, Loseto G, Capalbo S, Palumbo G, Cascavilla N.

Leuk Lymphoma. 2013 Dec;54(12):2660-6. doi: 10.3109/10428194.2013.789508. Epub 2013 May 15.

PMID:
23547840
44.

Cardiovascular events and intensity of treatment in polycythemia vera.

Marchioli R, Finazzi G, Specchia G, Cacciola R, Cavazzina R, Cilloni D, De Stefano V, Elli E, Iurlo A, Latagliata R, Lunghi F, Lunghi M, Marfisi RM, Musto P, Masciulli A, Musolino C, Cascavilla N, Quarta G, Randi ML, Rapezzi D, Ruggeri M, Rumi E, Scortechini AR, Santini S, Scarano M, Siragusa S, Spadea A, Tieghi A, Angelucci E, Visani G, Vannucchi AM, Barbui T; CYTO-PV Collaborative Group.

N Engl J Med. 2013 Jan 3;368(1):22-33. doi: 10.1056/NEJMoa1208500. Epub 2012 Dec 8.

45.

CD117-CD15 in acute myeloid leukemia: no role as LAIP in the study of minimal residual disease.

Rossi G, Nomdedéu Guinot JF, Fontana A, Minervini MM, García-Dabrio MC, Cascavilla N.

Eur J Haematol. 2013 Feb;90(2):171-4. doi: 10.1111/ejh.12042. Epub 2013 Jan 7. No abstract available.

PMID:
23167809
46.

Continuous lenalidomide treatment for newly diagnosed multiple myeloma.

Palumbo A, Hajek R, Delforge M, Kropff M, Petrucci MT, Catalano J, Gisslinger H, Wiktor-Jędrzejczak W, Zodelava M, Weisel K, Cascavilla N, Iosava G, Cavo M, Kloczko J, Bladé J, Beksac M, Spicka I, Plesner T, Radke J, Langer C, Ben Yehuda D, Corso A, Herbein L, Yu Z, Mei J, Jacques C, Dimopoulos MA; MM-015 Investigators.

N Engl J Med. 2012 May 10;366(19):1759-69. doi: 10.1056/NEJMoa1112704. Erratum in: N Engl J Med. 2012 Jul 19;367(3):285.

47.

Comparison between multiparameter flow cytometry and WT1-RNA quantification in monitoring minimal residual disease in acute myeloid leukemia without specific molecular targets.

Rossi G, Minervini MM, Carella AM, de Waure C, di Nardo F, Melillo L, D'Arena G, Zini G, Cascavilla N.

Leuk Res. 2012 Apr;36(4):401-6. doi: 10.1016/j.leukres.2011.11.020. Epub 2011 Dec 21.

PMID:
22196957
48.

An Italian retrospective study on the routine clinical use of low-dose alemtuzumab in relapsed/refractory chronic lymphocytic leukaemia patients.

Cortelezzi A, Gritti G, Laurenti L, Cuneo A, Ciolli S, Di Renzo N, Musto P, Mauro FR, Cascavilla N, Falchi L, Zallio F, Callea V, Maura F, Martinelli S, Piciocchi A, Reda G, Foà R; GIMEMA Chronic Lymphoproliferative Disorders Working Party.

Br J Haematol. 2012 Feb;156(4):481-9. doi: 10.1111/j.1365-2141.2011.08965.x. Epub 2011 Dec 9.

49.

Combination treatment of flag with non-pegylated liposomal doxorubicin (MYOCET(TM)) in elderly patients with acute myeloid leukemia: a single center experience.

Melillo L, Valente D, D'Arena G, Dell'Olio M, Falcone A, Minervini MM, Nobile M, Rossi G, Sanpaolo G, Scalzulli PR, Cascavilla N.

Int J Immunopathol Pharmacol. 2011 Jul-Sep;24(3):703-9.

PMID:
21978702
50.

Quality of life in elderly patients with essential thrombocythaemia. An Italian multicentre study.

Oliva EN, Piccin A, Mazzucconi MG, Morra E, Recine U, Pogliani EM, Pane F, Gobbi M, Gugliotta L, Krampera M, Cascavilla N, Cacciola R, Cacciola E, Fioritoni G, Fanin R, Liberati AM, Angelucci E, Tura S.

Ann Hematol. 2012 Apr;91(4):527-32. doi: 10.1007/s00277-011-1341-x. Epub 2011 Oct 1.

PMID:
21964878

Supplemental Content

Loading ...
Support Center